You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Bristol Myers Squibb is hoping that the durable responses seen with the combined immunotherapy drugs will convince doctors to prescribe it for their patients.
The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.
Results of the Phase II monarcHER study suggest that heavily pretreated HER2-positive breast cancer patients may be spared a chemotherapy-based regimen.
Through the Onco AI-Med collaboration, 30 partner institutions from 11 counties have access to IndivuMed's multiomics database and high-quality tissue sample repository.
Several genomic markers were associated with improved progression-free survival among patients treated with Tecentriq and Avastin versus Tecentriq alone.
In two studies, researchers showed the benefit of combining Tecentriq, Cotellic, and Zelboraf and sticking with continuous versus intermittent dosing of targeted drugs.
Though the Phase II results from the I-SPY 2 trial showed a potential benefit of the regimen in the neoadjuvant setting, additional data are needed.
The IPS-E prognostic tool, which draws on the presence of IGHV mutations as well as routine clinical lab tests, may also have added value in the midst of the COVID-19 pandemic.
With the help of a companion diagnostic, the firm plans to file a new drug application with the FDA for the previously abandoned TKI in the second half of 2020.